Prosecution Insights
Last updated: April 19, 2026
Application No. 18/448,304

Personal Care Compositions

Non-Final OA §102
Filed
Aug 11, 2023
Examiner
MI, QIUWEN
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Colgate-Palmolive Company
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
2y 7m
To Grant
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
1065 granted / 1565 resolved
+8.1% vs TC avg
Strong +50% interview lift
Without
With
+50.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
41 currently pending
Career history
1606
Total Applications
across all art units

Statute-Specific Performance

§101
10.9%
-29.1% vs TC avg
§103
38.4%
-1.6% vs TC avg
§102
25.8%
-14.2% vs TC avg
§112
19.1%
-20.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1565 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election/Restrictions Claims 47-72 are pending. Applicant’s election of Group II, claims 55-57, and 67-72, in the reply filed on 1/14/26 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). Claims 47-54, and 58-66 are withdrawn. Claims 55-57, and 67-72 are examined on the merits. Claim Objections Claim 72 is objected to because of the following informalities: Claim 72 recites “PPG” at line 4, which is incorrect. The full chemical name should be spelled out the first time a abbreviation appears in the claim. Claims 68, 69 and 71 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections –35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 55-57, 67, 70, and 72 are rejected under 35 U.S.C. 102 (a)(1) as being anticipated by Heok et al (KR 102408401 B1). Heok et al teach a composition comprising kangaroo paw extract 0.4 party by weight, colostrum powder 0.1 part by weight (thus a ferment; see below for explanation), palmitoyl tripeptide-1 0.007 part by weight (thus one or more peptide, thus claim 70 is met) , 0.003 part by weight of sodium hyaluronate, 0.003 part by weight of hydrolyzed hyaluronic acid (thus a hyaluronic acid system comprising a plurality of hyaluronic acid), 0.5 part by weight of glycerin (thus claim 72 is met, thus a humectant) [0172]. Heok et al teach a kangaroo claw flower extract is prepared by extracting the flowers of kangaroo claws [0103] (thus claim 57 is met). Heok et al teach a fermented solution containing culture medium and lactic acid bacteria (thus claim 67 is met) can be mixed with the enzyme-decomposed bovine colostrum [0143]. The fermented colostrum can be filtered to remove impurities, freeze-dried, and then pulverized to produce colostrum powder [0148] (thus a ferment, thus claim 67 us net). Therefore, the reference is deemed to anticipate the instant claim above. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to QIUWEN MI whose telephone number is (571)272-5984. The examiner can normally be reached on Monday-Friday 9:00 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached on 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Qiuwen Mi/ Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Aug 11, 2023
Application Filed
Jan 30, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599632
THERAPEUTIC AGENT FOR NERVE DISORDERS
2y 5m to grant Granted Apr 14, 2026
Patent 12599552
COSMETIC COMPOSITION CONTAINING EXTRACT OF CYPERUS ROTUNDUS FOR ANTI-INFLAMMATION, SKIN SOOTHING, IRRITATION RELIEF, AND SKIN BARRIER ENHANCEMENT
2y 5m to grant Granted Apr 14, 2026
Patent 12594233
FAT AND/OR WAX ACTIVATED BY MEANS OF THE WATER-INSOLUBLE FRACTION OF CARICA PAPAYA SAP
2y 5m to grant Granted Apr 07, 2026
Patent 12594316
PLANT COMPOSITION, TRADITIONAL CHINESE MEDICINE COMPOSITION AND USE THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12589121
METHOD FOR OBTAINING OCCLUSIVE BIOLOGICAL DRESSING, OCCLUSIVE BIOLOGICAL DRESSING, USE THEREOF AND KIT
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+50.0%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 1565 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month